Episode
#126 – The Opioid-Sparing Opioid – how to master perioperative methadone
- Podcast
- Anesthesia Guidebook
- Published
- Aug 11, 2026
- Duration seconds
- 5065
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/anesthesia-guidebook-1367573/episodes/126-the-opioid-sparing-opioid-how-to-master-perioperative-methadone/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/anesthesia-guidebook-1367573/126-the-opioid-sparing-opioid-how-to-master-perioperative-methadone.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
My guests today are Abigail Lee and Johanna Bennett, two Doctor of Nursing Practice graduate students at the University of New England who focused their DNP project on perioperative use of IV methadone. Abigail Lee attended Southern Maine Community College and transferred to the University of Southern Maine to study nursing. She worked at Maine Medical Center in the Cardiothoracic Intensive Care Unit. She intends to head down to North Carolina to work as a CRNA. Johanna Bennett went to Saint Anselm College. She started her career in healthcare in the Medical/COVID ICU as a new graduate nurse and worked there for three years before starting CRNA school at the University of New England. Jo will be joining our team at Maine Medical Center to work as a CRNA. This episode is on the longer side, so here’s your TL:DL, too-long; didn’t listen summary of perioperative IV methadone – the opioid-spairing opioid. Standard short-acting pure mu-agonists—like fentanyl, hydromorphone, and morphine—often leave our patients trapped in a roller coaster of ‘peaks and valleys,’ leading to oversedation, unexpected pain spikes, and high total opioid consumption in the PACU. In this episode, we explore why methadone is uniquely positioned as the ‘opioid-sparing opioid.’ Beyond its strong -receptor agonism, methadone boasts NMDA receptor antagonism and serotonin/norepinephrine reuptake inhibition, targeting pain at multiple pathways to blunt central sensitization and wind-up phenomenon. Key Clinical Takeaways from the Literature: The Effective Dose: An ideal single dose on induction is 0.2 to 0.25 mg/kg ideal body weight (or roughly 10-20 mgIV). Underdosing (<0.1 mg/kg) eliminates the long-term benefit, whil…